List view / Grid view
6 June 2014 | By Merck
Merck announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK...
6 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome...
6 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism...
5 June 2014 | By The European Medicines Agency
European regulatory authorities have finalised their assessment of reported non-compliance with Good Manufacturing Practice at Ranbaxy Laboratories’ manufacturing site...
4 June 2014 | By The European Medicines Agency
The European Medicines Agency has published a revised guideline on the acceptability of names for human medicines processed through the centralised procedure...
4 June 2014 | By Teva
Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities...
4 June 2014 | By Novartis
Novartis announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV). Jakavi® (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy...
4 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that by a letter dated June 2, the United States Food and Drug Administration has informed the Company about the closure of the Warning Letter...
4 June 2014 | By ARIAD Pharmaceuticals Inc
ARIAD Pharmaceuticals, Inc. announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig® (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia...
4 June 2014 | By Daiichi Sankyo
As announced in releases dated April 7 and 11, 2014, Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has entered into agreements with Sun Pharmaceutical Industries Ltd. (“Sun Pharma”) in connection with merger of Ranbaxy Laboratories Limited (“Ranbaxy”) into Sun Pharma. Daiichi Sankyo hereby announces additional information regarding the details of this…
3 June 2014 | By kdc communication
GlaxoSmithKline’s quest for improved anti-malarial treatments has been revolutionized by the speed and reliability of the HP D300 Digital Dispenser...
3 June 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product...
3 June 2014 | By Amgen
Amgen announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma...
3 June 2014 | By AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors...
3 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
